Details
This analysis evaluates the association between glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) and intentional self-harm in individuals with evidence of diabetes in the Sentinel Distributed Database (SDD). We identified individuals with incident use of GLP-1 receptor agonist (exposure) or SGLT2i (comparator) and evaluated the association between these products and intentional self-harm using inverse probability of treatment weighting (IPTW) to adjust for confounding. This updated analysis includes age and sex subgroup evaluations, providing further insights into the risk of intentional self-harm across demographic groups.
The study period includes data from October 1, 2015, to September 30, 2023. We distributed this request to six Sentinel Data Partners on September 20, 2024.
The analytic packages associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.